This is a working overview of metabolic modulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
This definition is much more practical, but an equilibrium constant defined in terms of concentrations is dependent on conditions. In particular, equilibrium constants for species in aqueous solution are dependent on ionic strength, as the quotient of activity coefficients varies with the ionic strength of the solution. The values of the standard free energy change and of the equilibrium constant are temperature dependent. To a first approximation, the van 't Hoff equation may be used.
This relates to having an increased risk of a woman bearing fraternal twins because higher levels of FSH will produce more eggs. The more eggs a woman produces increases the chance of multiple eggs ovulating and becoming fertilized by sperm. In retrospect, depending on the type of variation, the FSHB gene could potentially cause infertility by the inability to produce enough FSH, in both males and females. Additionally, low or no FSH can result in delayed puberty and risk of disease. Diseases associated with FSHB variants are hypogonadism, hypogonadotropic hypogonadism type 24 (HH24), and type 7 (HH7), and are possibly linked to polycystic ovary syndrome.
==== Amphetamines, harsher penalties, international obligations ==== During World War II (1939–1945), in addition to the widespread use of morphine, amphetamines entered military use to combat fatigue and improve morale. In the US, the Benzedrine brand was widely used in the military, and quickly became popular in the public for a variety of medical and recreational applications. Beginning in 1943, American soldiers could buy Benzedrine directly from the army on demand. Post-war, amphetamines were promoted as mood elevators and diet pills to great success; by 1945, an estimated 750 million tablets a year were being produced in the US, enough to provide a million people with a daily supply, a trend that grew during the 1950s and 1960s. Having failed to preserve world peace, the League of Nations ended post-war, transferring responsibilities to its successor, the United Nations. Anslinger, supported by Sharman, successfully campaigned to ensure that law enforcement and the prohibitionist view remained central to international drug policy. With the 1946 Lake Success Protocol, he helped to make sure that law enforcement was represented on the UN's new drug policy Supervisory Body (today's International Narcotics Control Board), and that it did not fall under a public health-oriented agency like the WHO. In the early 1950s, responding to "white suburban grassroots movements" concerned about dealers preying on teenagers, liberal politicians at state level cracked down on drugs.
Stretching of the atrial wall, via Atrial volume receptors Increased Sympathetic stimulation of β-adrenoceptors Increased sodium concentration (hypernatremia), though sodium concentration is not the direct stimulus for increased ANP secretion Endothelin, a potent vasoconstrictor Recently, it was discovered that ANP also can be O-glycosylated.
Sources: en.wikipedia.org
=== Rare === Suicide through disinhibition Psychosis Incontinence Paradoxical behavioural disinhibition (most frequently in children, the elderly, and in persons with developmental disabilities) Rage Excitement Impulsivity The long-term effects of clonazepam can include depression, disinhibition, and sexual dysfunction.
== January 16, 1982 (Saturday) == The United Kingdom and Vatican City established diplomatic relations at the ambassadorial level for the first time. In the state of Kerala in India, 24 people were killed in the sinking of an overcrowded boat as it was crossing Sasthamcotta Lake in poor weather, followed by a sinking of a boat that had come to the survivors' rescue."41 years since the Sasthamkotta Lake disaster", www.madhyamam.com (in Malayalam) Random drawings were held by FIFA at the Palacio de Congresos (Madrid) in Madrid for the grouping of the 24 teams that had qualified for the 1982 FIFA World Cup to be held in Spain starting on June 13. Of the 24 teams, divided by lot into six 4-team groups, 14 were UEFA members from Europe, 4 were CONMEBOL members from South America, 2 were CONCACAF teams from Central America, two from Africa, one (New Zealand) from Oceania and one (Kuwait) from the Middle East. National teams appearing for the first time in the World Cup were Honduras, New Zealand, Algeria, Cameroon and Kuwait. Born: Birgitte Hjort Sørensen, Danish stage, film and television actress known as co-star of the political drama series Borgen; in Hillerød Died: Marcel Francisci, 62, French businessman and smuggler accused of being the mastermind of the French Connection narcotics trafficking network, was shot to death in Paris as he was preparing to get into his car. Mahmud Yunus, 82, Indonesian Muslim preacher and author of 75 theological books
=== Other nonspecific signs === Some signs that may be present include changes in the nails (such as Muehrcke's lines, Terry's nails, and nail clubbing). Additional changes may be seen in the hands (Dupuytren's contracture) as well as the skin/bones (hypertrophic osteoarthropathy).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.